CFM
RARE icon

Catalyst Funds Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Catalyst Funds Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,400
Closed -$65.4K – 1515
2024
Q1 		$65.4K Buy
+1,400
New +$66K 0.02% 494

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Catalyst Funds Management's RARE Position: Q2 2024 in Review

Catalyst Funds Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 1,400 shares — an estimated $65.4K sold.

Catalyst Funds Management first reported a position in RARE in Q1 2024 and held it in 1 quarter. The position peaked at $65.4K in Q1 2024. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

  • Catalyst Funds Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,400 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $65.4K.
  • Catalyst Funds Management first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Ultragenyx Pharmaceutical position peaked at $65.4K in Q1 2024.
  • 274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.